LIMN MEXC RealStocks
Own real LIMN shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 21:44:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Liminatus Pharma, Inc. (LIMN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.95, with a market capitalization of $3.72M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.40 to $141.50. This page covers its latest market performance, valuation, price trends and company information.
$3.72M | |
$2.96 | |
$2.97 | |
$2.82 | |
$2.77 | |
13.44K | |
34.05K | |
-- | |
$141.50 | |
$2.40 | |
-- | |
-- |
Liminatus Pharma, Inc. (LIMN) is trading at $2.96 in after-hours trading as of 2026-11-13 21:38:00, up 0.41% ($0.01) from the regular-session close of $2.95.
After-hours trading shows how investors are pricing LIMN after the regular session closes. The current after-hours price is near the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Liminatus Pharma, Inc. (LIMN) moved from $2.63 to $2.95, representing a gain of 12.09% ($0.32).
The stock traded between $2.50 and $3.08 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 30.74 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.4%
LIMN is currently trading at $2.95, placing it 0.4% of the way from its 52-week low of $2.40 to its 52-week high of $141.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 1 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Liminatus Pharma, Inc. (LIMN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to LIMN, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between LIMN shares and USD.
LIMN Shares to USD
1.00 LIMN shares = 2.948 USD
Calculations are estimates based on the latest available price and are for reference only.